Islam Saqib 4
4 · ARS Pharmaceuticals, Inc. · Filed Jun 26, 2026
Research Summary
AI-generated summary of this filing
ARS Pharmaceuticals Director Islam Saqib Receives 30,000-Share Award
What Happened
Islam Saqib, a director of ARS Pharmaceuticals, was granted a derivative award of 30,000 shares on June 24, 2026. The reported acquisition price is $0.00 (derivative award), and the grant will vest in full on the earlier of June 24, 2027 or the date of the issuer's 2027 annual meeting of stockholders.
Key Details
- Transaction date: 2026-06-24; filing date (Form 4): 2026-06-26 (timely filed).
- Type: Award/Grant (derivative); amount: 30,000 shares; reported acquisition price: $0.00.
- Vesting: Full vesting on earlier of June 24, 2027 or the Issuer’s 2027 annual meeting (footnote F1).
- Shares owned after transaction: not specified in this filing.
- No sale or exercise occurred — this is a compensation grant, not a market purchase or sale.
Context
This is a compensation-related derivative grant (likely stock options or RSUs) that vests over time; it does not represent an immediate purchase or sale of stock. Such awards are common for directors and reflect compensation rather than a direct signal to buy or sell shares.
Insider Transaction Report
Form 4
Islam Saqib
Director
Transactions
- Award
Stock Option (right to buy)
[F1]2026-06-24+30,000→ 30,000 totalExercise: $10.54Exp: 2036-06-23→ Common Stock (30,000 underlying)
Footnotes (1)
- [F1]The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Signature
/s/ Kathleen Scott, Attorney-in-Fact|2026-06-26